COMPUESTOS DE QUINOLINA Y QUINOXALINA

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5,R6,R7,J, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES DE LA HMG COA REDUCTASA POR LO QUE SON DE UTILIDAD EN CUADROS TALES DISLIPIDEMIA, HIPERBETALIPOPROTEINEMIA, HIPERCO...

Full description

Saved in:
Bibliographic Details
Main Authors JARI ILMARI FINNEMAN, DAVID AUSTEN PERRY, RYAN MICHAEL KELLEY, MARY THERESA DIDIUK, ROGER BANJAMIN RUGGERI, GEORGE CHANG, RAVI SHANKER GARIGIPATI, BRUCE MICHAEL BECHLE
Format Patent
LanguageSpanish
Published 02.03.2005
Edition6
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE FORMULA GENERAL I EN LA QUE R1,R2,R3,R4,R5,R6,R7,J, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES DE LA HMG COA REDUCTASA POR LO QUE SON DE UTILIDAD EN CUADROS TALES DISLIPIDEMIA, HIPERBETALIPOPROTEINEMIA, HIPERCOLESTEROLEMIA, ENTRE OTROS MENCIONADOS EN LA SOLICITUD. Quinoline and quinoxaline compounds of formula I and III wherein the subtituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Bibliography:Application Number: GT20040000050